A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
暂无分享,去创建一个
C. Verschraegen | A. Kudelka | B. Giovanella | R. Freedman | E. Loyer | J. Kavanagh | E. Gupta | J. Stehlin | C. Edwards | N. Harris | M. Steger | V. Steltz